{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-006817","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.159771+00:00","generated_at":"2026-06-05T02:31:52.384150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Talphera Q4 net loss $4.5M; cash $9.4M; Niyad study enrollment imminent; $26M committed","bullets":["Net loss from continuing ops of $4.5M ($0.25/sh) vs $5.9M ($1.00/sh) in Q4 2022; revenues $0.3M.","Cash and investments $9.4M at Dec 31, 2023; senior debt fully repaid in Q2 2023.","Jan 2024: $26M committed capital — $8M DSUVIA royalty monetization with Xoma + $18M equity from two investors.","First patient enrollment in NEPHRO CRRT registrational study expected Q1 2024; PMA submission targeted by end 2024.","Company rebranded from AcelRx to Talphera in Jan 2024; now trades as TLPH on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-006817","json":"https://secwatch.observer/filing/0001437749-24-006817.json","markdown":"https://secwatch.observer/filing/0001437749-24-006817.md","text":"https://secwatch.observer/filing/0001437749-24-006817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/0001437749-24-006817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/acrx20240305_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:31:52.384150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9a55aeeb362c5f09a10e256f73785bf23ebe9d9","claim":"TALPHERA, INC. reported the three months ended December 31, 2023 results: revenue $0.3 million, net income $4.5 million, EPS $0.25 per basic and diluted share.","evidence_excerpt":"● The cash and cash equivalents balance was $9.4 million as of December 31, 2023. The senior debt with Oxford was fully repaid in the second quarter of 2023. ● Revenues of $0.3 million for the fourth quarter primarily represent the revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the prior","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/0001437749-24-006817-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Revenue","value":"$0.3 million"},{"label":"Net income","value":"$4.5 million"},{"label":"EPS","value":"$0.25 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}